Question
Why was I turned away from a clinical trial for a low neutrophil count?
Short answer
In phase 3 trials for prostate, breast, melanoma, colorectal and lung cancer from 2021 to 2023, 221 of 289 eligible trials (76.5%) excluded patients whose neutrophil counts were within the Duffy-null range. If you are about to start chemotherapy or a clinical trial and were told your count is too low, see a haematologist or oncologist and ask about Duffy-null.
What this is based on
- Who was tested: Phase 3 cancer trials for prostate, breast, melanoma, colorectal and lung cancers, 2021-2023. What was found: Of 289 eligible trials, 221 (76.5%, 95% CI 71.1-81.2) excluded patients whose neutrophil counts were within the Duffy-null reference range. Colorectal trials had the highest exclusion proportion (86.4%), prostate the lowest (47.8%).Tested Hibbs 2024 Study page
- You are about to start chemotherapy or a clinical trial and were told your count is too low (haematologist or oncologist: ask about Duffy-null).When to see someone
From the card
Many people of African ancestry are Duffy-null, an inherited blood-cell variant that gives a lower neutrophil count (the white cells that fight infection). The main study calls it clinically insignificant. The risk is being misread: a normal count for you can be flagged as low.
Where this comes from
- Merz 2023 (Study page) Open source
- Reich 2009 (Study page) Open source
- Hibbs 2024 (Study page) Open source
- Hibbs 2025 (Study page) Open source
- Abdallah 2024 (Study page) Open source
Read the full entry: A low white cell count that may be Duffy-null (neutrophil count)
Last checked against its sources: . Next check due: 16 May 2027.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence.